MalariaWorld Events's blog
MESA is very excited to be launching its new website and knowledge management tools at ASTMH in New Orleans on November 2nd!
The Second Global Malaria Action Plan (GMAP2) will cover the timeframe 2016-2025.
You are strongly encouraged to have a look and contribute by sharing your vision for a malaria-free world.
Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.
Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.